Article
Author(s):
Pharmacists working collaboratively can make an impact, including for patients with more acute diseases.
Pharmacists cannot operate in silos. Even amidst turf wars that might exist among some health professionals, the best outcomes are usually the result of collaboration. Many pharmacy services are directed toward chronic illnesses such as diabetes, and hypertension, because the majority of patients have to live with these diseases for a long time, and interventions can help save money and improve quality of life. But there are many instances where pharmacists working collaboratively can make an impact, including for patients with more acute diseases.
A study published in the Journal of Oncology Practice hypothesized that a multidisciplinary collaborative physician-pharmacist multiple myeloma clinic would improve adherence to treatment and supportive care guidelines, as well as reduce delays in receiving oral antimyeloma therapy. In this study, an oncology pharmacist provided consultation for all patients in a specialist myeloma clinic. This included reviewing medications, ensuring physician adherence to supportive care guidelines, managing treatment-related adverse effects, and navigating issues involving access to oral specialty medications (collaborative clinic). Outcome measures were retrospectively compared with those of patients being treated by the same physician during the previous year, in which ad hoc pharmacist consultation was available upon request, only (traditional clinic).
Use of the collaborative clinic led to significant improvements in patient adherence to supportive medications, such as bisphosphonates, calcium and vitamin D, acyclovir, and pneumonia prophylaxis. Appropriate venous thromboembolism prophylaxis in immunomodulatory drug-treated patients was prescribed in 100% versus 83% of cases in the collaborative vs traditional clinic, respectively. The median time to initiation of bisphosphonate was shortened substantially (a few days vs. nearly 100 days). The number and duration of delays in obtaining drug therapy were also significantly reduced.
There are clinical endpoints, intermediate clinical outcomes, and process of care measures. While clinical endpoints are often the end goal, other outcomes measures are not unimportant. Pharmacy managers can work collaboratively to identify important outcomes for treatment in a broad array of diseases, such as in this case with adherence and reduction in delays to time-sensitive medications. There are so many ways (both obvious and more subtle) that pharmacy services can be beneficial.
Additional information about medication therapy management and management functions can be found in Pharmacy Management: Essentials for All Practice Settings, 5e. You or your institution can subscribe to AccessPharmacy to access the textbook.
Shane P. Desselle, RPh, PhD, FAPhA, is Professor of Social/Behavioral Pharmacy at Touro University California. He is author of Chapter 1: The “Management” in Medication Therapy Management and Management Functions in the textbook Pharmacy Management: Essentials for All Practice Settings, 5e.
REFERENCES
Sweiss K, Wirth SM, Sharp L, et al. Collaborative physician-pharmacist-managed multiple myeloma clinic improves guideline adherence and prevents treatment delays. J Oncol Pract. 2018;14:e674-682.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa